(PAHC) Phibro Animal Health - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.366m USD | Total Return: 26.5% in 12m
Avg Turnover: 14.5M
EPS Trend: 92.3%
Qual. Beats: 0
Rev. Trend: 95.7%
Qual. Beats: 4
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Phibro Animal Health Corporation (NASDAQ: PAHC) is a global provider of animal health and mineral nutrition products, serving the livestock, aquaculture, and companion animal markets. The company operates through three primary segments: Animal Health, Mineral Nutrition, and Performance Products. Its portfolio includes antibacterials, vaccines, nutritional specialties, and trace minerals designed to improve animal welfare and food production efficiency.
The business model relies on a direct sales force and distribution network targeting integrated producers and commercial feed manufacturers. The animal health sector is characterized by high regulatory barriers and a steady demand tied to global protein consumption. Unlike human pharmaceuticals, animal health products often face shorter clinical development cycles and lower R&D costs relative to product lifespans.
For a deeper look into the companys valuation metrics and historical performance, consider reviewing the detailed analysis available on ValueRay. Phibro remains headquartered in Teaneck, New Jersey, and maintains a diverse geographic footprint across North America, Europe, and the Asia Pacific region.
- Livestock commodity prices and feed demand drive Animal Health segment revenue
- Rising input costs for trace minerals impact Mineral Nutrition segment margins
- Regulatory scrutiny of medicated feed additives threatens long-term core product sales
- Expansion into companion animal vaccines diversifies revenue away from livestock cycles
- Global protein consumption trends dictate demand for nutritional specialties and vaccines
| Net Income: 95.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.84 > 1.0 |
| NWC/Revenue: 40.81% < 20% (prev 42.79%; Δ -1.98% < -1%) |
| CFO/TA 0.05 > 3% & CFO 66.1m > Net Income 95.2m |
| Net Debt (761.9m) to EBITDA (235.0m): 3.24 < 3 |
| Current Ratio: 3.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.0m) vs 12m ago 0.81% < -2% |
| Gross Margin: 32.54% > 18% (prev 0.32%; Δ 3.22k% > 0.5%) |
| Asset Turnover: 108.6% > 50% (prev 90.39%; Δ 18.21% > 0%) |
| Interest Coverage Ratio: 4.02 > 6 (EBITDA TTM 235.0m / Interest Expense TTM 45.9m) |
| A: 0.42 (Total Current Assets 894.1m - Total Current Liabilities 281.9m) / Total Assets 1.45b |
| B: 0.23 (Retained Earnings 336.1m / Total Assets 1.45b) |
| C: 0.13 (EBIT TTM 184.4m / Avg Total Assets 1.38b) |
| D: 0.21 (Book Value of Equity 223.6m / Total Liabilities 1.08b) |
| Altman-Z'' = 4.65 = AA |
| DSRI: 0.89 (Receivables 221.5m/197.5m, Revenue 1.50b/1.19b) |
| GMI: 0.97 (GM 32.54% / 31.67%) |
| AQI: 0.80 (AQ_t 0.10 / AQ_t-1 0.12) |
| SGI: 1.26 (Revenue 1.50b / 1.19b) |
| TATA: 0.02 (NI 95.2m - CFO 66.1m) / TA 1.45b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 30.79 with a total of 339,127 shares traded.
Over the past week, the price has changed by -7.98%,
over one month by -41.35%,
over three months by -43.47% and
over the past year by +26.52%.
Phibro Animal Health has received a consensus analysts rating of 2.50. Therefore, it is recommended to sell PAHC.
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 45.6 | 48.1% |
P/E Trailing = 14.4549
P/E Forward = 13.8313
P/S = 0.9108
P/B = 3.7266
P/EG = 1.6791
Revenue TTM = 1.50b USD
EBIT TTM = 184.4m USD
EBITDA TTM = 235.0m USD
Long Term Debt = 712.7m USD (from longTermDebt, last quarter)
Short Term Debt = 32.2m USD (from shortTermDebt, last quarter)
Debt = 839.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.9m
Net Debt = 761.9m USD (calculated: Debt 839.4m - CCE 77.5m)
Enterprise Value = 2.13b USD (1.37b + Debt 839.4m - CCE 77.5m)
Interest Coverage Ratio = 4.02 (Ebit TTM 184.4m / Interest Expense TTM 45.9m)
EV/FCF = 166.6x (Enterprise Value 2.13b / FCF TTM 12.8m)
FCF Yield = 0.60% (FCF TTM 12.8m / Enterprise Value 2.13b)
FCF Margin = 0.85% (FCF TTM 12.8m / Revenue TTM 1.50b)
Net Margin = 6.35% (Net Income TTM 95.2m / Revenue TTM 1.50b)
Gross Margin = 32.54% ((Revenue TTM 1.50b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 32.77% (prev 35.48%)
Tobins Q-Ratio = 1.47 (Enterprise Value 2.13b / Total Assets 1.45b)
Interest Expense / Debt = 5.47% (Interest Expense 45.9m / Debt 839.4m)
Taxrate = 25.65% (8.29m / 32.3m)
NOPAT = 137.1m (EBIT 184.4m * (1 - 25.65%))
Current Ratio = 3.17 (Total Current Assets 894.1m / Total Current Liabilities 281.9m)
Debt / Equity = 2.32 (Debt 839.4m / totalStockholderEquity, last quarter 361.8m)
Debt / EBITDA = 3.24 (Net Debt 761.9m / EBITDA 235.0m)
Debt / FCF = 59.66 (Net Debt 761.9m / FCF TTM 12.8m)
Total Stockholder Equity = 322.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.90% (Net Income 95.2m / Total Assets 1.45b)
RoE = 29.49% (Net Income TTM 95.2m / Total Stockholder Equity 322.9m)
RoCE = 17.81% (EBIT 184.4m / Capital Employed (Equity 322.9m + L.T.Debt 712.7m))
RoIC = 12.26% (NOPAT 137.1m / Invested Capital 1.12b)
WACC = 8.16% (E(1.37b)/V(2.21b) * Re(10.68%) + D(839.4m)/V(2.21b) * Rd(5.47%) * (1-Tc(0.26)))
Discount Rate = 10.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 0.58%
[DCF] Terminal Value 73.10% ; FCFF base≈27.3m ; Y1≈23.9m ; Y5≈19.3m
[DCF] Fair Price = N/A (negative equity: EV 310.3m - Net Debt 761.9m = -451.6m; debt exceeds intrinsic value)
EPS Correlation: 92.30 | EPS CAGR: 45.61% | SUE: 0.75 | # QB: 0
Revenue Correlation: 95.68 | Revenue CAGR: 19.37% | SUE: 1.55 | # QB: 4
EPS next Quarter (2026-09-30): EPS=0.79 | Chg30d=-2.47% | Revisions=-20% | Analysts=1
EPS current Year (2026-06-30): EPS=3.07 | Chg30d=+1.59% | Revisions=+50% | GrowthEPS=+47.0% | GrowthRev=+15.6%
EPS next Year (2027-06-30): EPS=3.34 | Chg30d=-0.59% | Revisions=+14% | GrowthEPS=+8.8% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: +50%